Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
about
Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
description
2019 nî lūn-bûn
@nan
2019年の論文
@ja
2019年学术文章
@wuu
2019年学术文章
@zh
2019年学术文章
@zh-cn
2019年学术文章
@zh-hans
2019年学术文章
@zh-my
2019年学术文章
@zh-sg
2019年學術文章
@yue
2019年學術文章
@zh-hant
name
Cost-effectiveness of abatacep ...... c drug in rheumatoid arthritis
@en
type
label
Cost-effectiveness of abatacep ...... c drug in rheumatoid arthritis
@en
prefLabel
Cost-effectiveness of abatacep ...... c drug in rheumatoid arthritis
@en
P2093
P1433
P1476
Cost-effectiveness of abatacep ...... c drug in rheumatoid arthritis
@en
P2093
Dan Nordström
Jaana Viikinkoski
Jarno Rutanen
Kalle J Aaltonen
Kari Puolakka
Kirsi Taimen
Marja Blom
P304
P356
10.1371/JOURNAL.PONE.0220142
P577
2019-07-24T00:00:00Z